This is a pre-announced, rules-based tender offer under BMEZ's discount management program — not a discretionary buy signal. Monitor the proration level at expiration: if heavily oversubscribed, remaining shareholders see a modest NAV uplift from the 2% discount to NAV; if undersubscribed, the discount management program's credibility may weaken. Watch for any extension or amendment announcements before the Nov 18 deadline.
Price Chart
Executive Summary
BlackRock Health Sciences Term Trust (BMEZ) is launching an issuer tender offer to repurchase up to 5% of its outstanding common shares (approximately 3.125 million shares) at 98% of NAV per share, triggered by its discount management program after shares traded at an average daily discount to NAV exceeding 10% during a 9-month measurement period. The offer expires November 18, 2026, and is funded from cash on hand and portfolio security sales, with no borrowing planned. This is a mechanical, pre-announced program response to persistent discount, not a discretionary signal of undervaluation.
Key Financial Metrics
Key Facts
- Fund offers to buy up to 5% of outstanding shares (3,125,070 shares) at 98% of NAV per share
- Offer expires 5:00 p.m. ET on November 18, 2026, unless extended
- Triggered by average daily discount to NAV >10% during 9-month measurement period ended September 30, 2026
- Purchase price based on NAV on trading day after expiration; estimated cost ~$56.4 million at Oct 9, 2026 NAV
- Funded first from cash on hand, then from selling portfolio securities; no borrowing planned
- As of Oct 9, 2026: NAV $18.42, market price $16.52, discount (10.31)%
- None of the Board, officers, or portfolio managers intend to tender shares
- Standstill agreements exist with Karpus Management (through May 3, 2027) and Saba Capital (through 2027 annual meeting or Aug 31, 2027)
Financial Impact
Up to ~$56.4 million cash outflow for share repurchase at 98% of NAV; reduces fund assets by ~5%
Risk Factors
- Selling portfolio securities to fund the offer may realize capital gains, creating taxable distributions for remaining shareholders
- Reduced asset base may increase expense ratio and limit investment flexibility/leverage
- If heavily oversubscribed, pro-rata acceptance means many tendering shareholders retain unwanted exposure
- No guarantee the offer will narrow the persistent discount to NAV
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-I Filing (Primary) | 0001193125-26-424214 |
| Document: d188931dex99a1ii.htm | 0001193125-26-424214 |
| Document: d188931dsctoi.htm | 0001193125-26-424214 |
| Document: d188931dexfilingfees.htm | 0001193125-26-424214 |
| Document: 0001193125-26-424214-index-headers.html | 0001193125-26-424214 |
| Document: 0001193125-26-424214-index.html | 0001193125-26-424214 |
| Document: 0001193125-26-424214.txt | 0001193125-26-424214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | SC TO-I | $16.44 | awaiting T+20 | — | $17.28 (+5.11%) |
Oct 1, 2026 26d ago | SC TO-C | $16.47 | awaiting T+20 | — | $17.28 (+4.92%) |
Aug 5, 2026 11w ago | 3 | $15.71 $16.94 | ▲ +7.83% | ▲ +7.23% | $17.28 (+9.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers